Vaccine Development

News-EN·Personalized Medicine·Vaccine Development·xPL

Is Moderna Bouncing Back? Uncovering Their Future Path

Moderna’s stock experienced a dramatic 58% fall in 2024, primarily due to declining demand for its COVID-19 vaccine and a slow start for its RSV vaccine. Projected 2024 revenues of $2.3 billion represent a 44% decrease, highlighting the financial impact of its

February 22, 2025

Data Privacy·Data Visualization·Drug Discovery·Genomics·News-EN·Personalized Medicine·Vaccine Development·xPL·xTR

The AI Revolution You Didn’t See Coming: Why China and Small Players are the New Trailblazers

Artificial intelligence innovation is shifting towards China and agile firms like Recursion Pharmaceuticals, challenging traditional tech giants. Recursion Pharmaceuticals exemplifies this by leveraging AI for rapid drug discovery with limited resources, using 1,500 GPUs to expand drug hypotheses significantly. This trend showcases

February 21, 2025

Infection Risk·News-EN·Quality Control·Vaccine Development

Dynavax Technologies Poised for a Groundbreaking Year: A Vaccine Revolution

Dynavax Technologies reports record-breaking revenues driven by their HEPLISAV-B hepatitis B vaccine, capturing 44% of the U.S. market. The company projects 2025 revenues to soar between $305 million and $325 million, underscoring their dominant market presence. Dynavax aims to revolutionize the shingles

February 21, 2025

AI in Healthcare·Cancer Detection·News-EN·Personalized Medicine·Vaccine Development

Can Trump’s AI Initiative Heal the Rift? Vaccine Skeptics in Uproar

In a bold move, former President Donald Trump unveiled an ambitious AI infrastructure initiative, drawing varied reactions from his supporters and vaccine skeptics. Named Stargate, this development, with an estimated cost of up to $500 billion, promises to generate over 100,000 jobs

January 22, 2025

News-EN·Vaccine Development·xIT·xPL

Pharmaceutical Giant’s Unexpected Turn. What Lies Ahead?

Pfizer, a notable figure in the pharmaceutical industry, is experiencing a transformative phase after the pandemic-era boom. Once dominating the market with its COVID-19 vaccine, Pfizer’s valuation has significantly contracted, moving from an impressive $333.8 billion peak to about $150 billion. This

January 18, 2025

News-EN·Vaccine Development

Moderna’s Stocks Plunge: Is This the End or a Buying Opportunity?

Shares Fall After Disheartening Updates Modern’s recent performance has been alarming, with the company facing a significant decline. The firm shared a business and pipeline update at the J.P. Morgan Healthcare Conference, which caused its stock to plummet nearly 17%. This drop

January 15, 2025

News-EN·Vaccine Development

Moderna’s Stock Takes a Nosedive: What Went Wrong?

In a startling twist, Moderna’s stock has plummeted dramatically, leaving investors reeling. Earlier this month, the company enjoyed a significant surge, rising from $39.38 to $47.43 in just a week, fueled by impressive quarterly earnings and a hefty $176 million award aimed

January 13, 2025

News-EN·Vaccine Development

New Analysis Sparks Stock Surge! Emergent BioSolutions Soars

Emergent BioSolutions: A Rising Star in the Healthcare Sector As the last trading week of 2024 began, Emergent BioSolutions experienced a remarkable surge in its stock price, climbing nearly 12% in a single day. This impressive rise stood in stark contrast to

December 30, 2024

News-EN·Vaccine Development·xIT·xPL·xTR

hVIVO’s Rollercoaster Ride! Can This Stock Bounce Back?

The Intriguing World of hVIVO: Ups and Downs in 2024 The stock market can often resemble a rollercoaster, and hVIVO is no stranger to such thrilling rides. This dynamic company saw its share price soar from 11p in late 2022 to a

December 28, 2024

News-EN·Personalized Medicine·Vaccine Development·xPL

Pfizer’s New Forecast: Reasons to Buy or Beware?

A Closer Look at Pfizer’s Projections Despite facing unusual pressure from shareholders eager for a shake-up, Pfizer (PFE 2.29%) remains optimistic about its future. The pharmaceutical giant recently unveiled its forecasts for 2024 and 2025, emphasizing a commitment to cost control and

December 22, 2024

News-EN·Vaccine Development·xIT·xPL

You Won’t Believe Pfizer’s Latest Move! Is Now the Time to Invest?

Pfizer, once hailed globally for pioneering the first FDA-approved Covid vaccine, is witnessing a dramatic shift in its fortunes. At its peak during the pandemic, the pharmaceutical giant’s market value soared to $333.8 billion. Fast forward to now, its valuation has plummeted

December 14, 2024

Artificial Intelligence (AI)·Autonomous Vehicles·Cloud Computing·News-EN·Personalized Medicine·Vaccine Development·xCH·xPL·xTR

Stocks Soar to New Heights! The Future of Investments in the Tech Era

In a world increasingly driven by technology, the stock market is experiencing unprecedented booms, as tech stocks lead the charge. The term 株価高騰 or “stock prices soaring” encapsulates this phenomenon, where innovation and investment meet to form a powerful alliance with

December 2, 2024